NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









IASO Bio

IASO Bio

Private
NanjingHealthcare & Life Scienceshttps://iasobio.com

Last Round

Series C

Extension

Sep 1, 2025

Total Funding Raised

$303.4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

IASO Bio is a biopharmaceutical company that develops innovative cell therapies and biologics for the treatment of hematological malignancies and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

CAR-T therapycell therapymultiple myelomaequecabtagene autoleucelBCMA targetinghematological cancerbiopharmaceuticalantibody discoveryliving drugscancer immunotherapyclinical-stage biotechdrug licensingnext-gen oncologyCAR-T pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IASO Bio Comps

Public and private peers based on sector, stage, and business model.

IASO Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

IASO Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionSep 1, 2025
StrategicJul 5, 2024
Series C ExtensionJan 17, 2023
Series CSep 16, 2021
Series BMar 24, 2020
Series A
Oct 1, 2019

IASO Bio Investors

Notable investors and investment history

IASO Bio investors
InvestorRounds
Hongcheng CapitalSeries C Extension
CDH InvestmentsSeries C
CNCB InvestmentSeries C
CDH BaifuSeries C
Hillhouse InvestmentSeries B, Series A
Housen Care BrothersSeries C Extension
CCB InternationalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    Partnered with Instituto Butantan to expand access in Brazil.

  • Oct 29, 2025

    Partnered with GC Cell to enter the Korean market.

IASO Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

IASO Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about IASO Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNanjing
Employee Range55
Year Founded2017
Last FundingSep 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.